Next Article in Journal
Comparison of Myocardial Perfusion Scintigraphy and Coronary Angiography Results in Breast Cancer Patients Treated with Radiotherapy
Previous Article in Journal
Trimodality Treatment of Superior Sulcus Non-Small Cell Lung Cancer: An Institutional Series of 47 Consecutive Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 30
Issue 5
10.3390/curroncol30050345
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clinical Profile and Predictors of Survival in Carcinoma Penis Patients

by
Vikas Garg
1,
Mukurdipi Ray
2,
K. P. Haresh
3,
Ranjit Kumar Sahoo
1,
Atul Sharma
1,
Seema Kaushal
4 and
Atul Batra
1,*
1
Department of Medical Oncology, BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Delhi 110029, India
2
Department of Surgical Oncology, BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Delhi 110029, India
3
Department of Radiation Oncology, BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Delhi 110029, India
4
Department of Pathology, All India Institute of Medical Sciences, Delhi 110029, India
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2023, 30(5), 4563-4574; https://doi.org/10.3390/curroncol30050345
Submission received: 9 March 2023 / Revised: 4 April 2023 / Accepted: 5 April 2023 / Published: 28 April 2023
(This article belongs to the Section Genitourinary Oncology)
Browse Figure
Review Reports Versions Notes

Abstract

:
Background: Carcinoma penis is a rare neoplasm, and the literature is scarce on long-term survival and its predictors. The aim of the study was to determine the clinical profile and management patterns, identify predictors of survival, and the impact of education and rural/urban dwelling on survival. Methods: Patients with a histological diagnosis of carcinoma penis from January 2015 to December 2019 were included in the study. Demographics, clinical profile, education status, primary residence address, and outcomes were obtained from the case records. Distance from the treatment centre was obtained from the postal code. The primary objectives were to assess relapse-free survival (RFS) and overall survival (OS). The secondary objectives were to identify the predictors of RFS and OS and to determine the clinical profile and treatment patterns in patients with carcinoma penis in India. Time-to-event was calculated by Kaplan–Meir analysis and survival was compared by the log-rank test. Univariate and multivariable Cox regression analyses were used to find independent predictors of relapse and mortality. Logistic regression analyses to examine the associations of rural residence, education status, and distance from the treatment centre with the relapse adjusting for measured confounding variables. Results: Case records of 102 patients treated during the above period were retrieved. The median age was 55.5 (interquartile range [IQR] 42–65 years). Ulcero-proliferative growth (65%), pain (57%), and dysuria (36%) were the most common presenting features. Clinical examination or imaging revealed inguinal lymphadenopathy in 70.6% of patients, however, only 42% of these lesions were pathologically involved. A total of 58.8% of patients were from rural areas, 46.9% had no formal education, and 50.9% had a primary residence ≥100 km from the hospital. Patients with lower education and rural households had higher TNM stages and nodal involvement. Median RFS and OS were 57.6 months (15.8 months to not reached) and 83.9 months (32.5 months to not reached), respectively. On univariate analysis tumor stage, involvement of lymph nodes, T stage, performance status, and albumin was predictive for relapse and survival. However, on multivariate analysis, the stage remained the only predictor of RFS and nodal involvement, and metastatic disease was a predictor of OS. Education status, rural habitation, and distance from the treatment centre were not predictors for relapse or survival. Conclusions: Patients with carcinoma have locally advanced disease at presentation. Rural dwellings and lower education were associated with the advanced stage but did not have a significant bearing on the survival outcomes. The stage at diagnosis and nodal involvement is the most important predictor of RFS and OS.

1. Introduction

Penile cancer is an uncommon malignancy of the genitourinary system accounting for less than one percent of adult malignancies in developed countries [1]. However, it is relatively common in the developing world and may account for up to 10% of all cancers in men in some African and South American countries [2,3]. In India, the estimated incidence rate is 0.8 per 100,000 according to the recent population-based cancer registry report [4].
It is a disease of elderly men with a median age of 60 years and usually presents as an ulcero-proliferative growth over the penis [5,6]. It spreads via lymphatics to involve inguinal lymph nodes and subsequently, pelvic and retroperitoneal lymph nodes. Inguinal lymph node involvement is common at presentation (30–60%), however distant metastasis is rare at diagnosis (<10%) [7].
Squamous cell carcinoma is the most prevalent subtype, accounting for approximately 95% of all cases. Less common varieties include papillary, condylomatous, basaloid, verrucous, and sarcomatoid carcinoma [8]. Risk factors for the development of carcinoma penis include genital warts, poor hygiene, urinary tract infections, penile tear, penile injury, phimosis, human immunodeficiency virus (HIV) infection, and smoking [9,10]. Infection with the human papilloma virus (HPV), particularly types 16 and 18, which can be identified in up to 50% of squamous cell carcinoma patients, is frequently linked to favourable outcomes [11,12,13]. Tumor stage, grade, lymph node involvement, Ki-67, and HPV status are considered the most important prognostic factors [14,15].
The primary treatment for penile cancer is surgical, although in very low-risk cases organ preserving therapies like laser therapy or brachytherapy may be employed [16,17,18]. Lymph node staging is an important part of management and may be done by either fine needle aspiration cytology (FNAC), superficial inguinal lymph node dissection (ILND), or dynamic sentinel node biopsy (DSNB) [19]. The role of neoadjuvant chemotherapy is limited to patients presenting with unresectable primary, bulky, or bilateral inguinal lymph nodes, or pre-operative imaging suggestive of pelvic lymphadenopathy [20,21,22]. Adjuvant chemotherapy is indicated in the presence of bilateral or multiple inguinal lymph nodes, extranodal extension (ENE), or pelvic lymph node involvement [23]. Metastatic disease is treated with palliative intent with platinum-based chemotherapy [24,25].
The literature on the clinical profile and treatment outcomes in Indian patients with carcinoma penis is scarce. The impact of education status, rural versus urban dwelling, and distance from the treatment centre has not been reported in India. The objective of this study was to determine the clinical profile, management patterns, and treatment outcomes in patients with carcinoma penis. Further, we identified factors that predict survival and studied the impact of education, rural habitation, and distance from a treatment centre. Understanding the profile and predictors of survival in these patients can help devise strategies to better prognosticate and manage patients effectively.

2. Materials and Methods

Methodology

This retrospective study was conducted at the Department of Medical Oncology of a tertiary care centre in India after approval from the institute’s ethics review board. Patients ≥18 years of age with a histological diagnosis of carcinoma penis from January 2015 to December 2019 were included in the study. Baseline demographics profile, education status, primary residence address, presenting symptoms, staging, histopathologic features, detailed treatment summary, and response to treatment, were obtained from case records. Management including treatment modality (surgery, radiation therapy, chemotherapy, or combination) and intent of management viz. curative, or palliative was also recorded. Palliative therapy was used to describe any treatment modality administered in cases where a cure was not anticipated. The staging was done according to the American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) seventh edition staging system [26]. Distance from the treatment centre was obtained from the postal code. The rural area was denoted as per the census of India 2011, which has a population of less than 5000, a density of population of less than 400 per square km, and more than 25 percent of the male working population is engaged in agricultural pursuits [27]. The date of diagnosis, date of relapse, duration between diagnosis to death, or last follow-up were also recorded.
The primary objectives were to assess the relapse-free survival (RFS) and overall survival (OS) in patients with carcinoma penis. The secondary objectives were to identify the predictors of RFS and OS and to determine the clinical and demographic profile and treatment patterns in patients with carcinoma penis in India. Relapse-free survival was defined as the period from the date of initial surgery or other curative treatment to the date of relapse. Overall survival (OS) was defined as the period from the date of diagnosis to death due to any cause. Data were censored at the most recent follow-up.

3. Statistical Analysis

Data were analyzed by Stata 14 (4905 Lakeway Drive, College Station, TX, USA) and presented in mean ± standard deviation (SD)/median (range) and frequency (percentage). Categorical variables were compared by Chi-square or Fisher’s exact test. Continuous variables following normal distribution were compared by independent t-test. Data not following normal distribution was compared by the Wilcoxon Rank sum test. Time-to-event was calculated by Kaplan–Meir analysis and survival was compared using the log-rank test. Univariate and multivariable Cox regression analysis was used to find independent predictors of survival and mortality. Adjusted/unadjusted death or last follow-up was used for calculating the hazard ratio. A p-value <0.05 was considered statistically significant.

4. Results

Demographic Data

A total of 102 patients with histological diagnoses of carcinoma penis were treated from January 2015 to December 2019. The baseline clinical characteristics of patients with carcinoma penis are summarized in Table 1. The median age of the population was 55.5 years (interquartile range [IQR] 42–65 years) and the median duration from symptom onset to diagnosis was 6.0 months (IQR, 4–12 months). Smoking was the most common (27.5%) risk factor associated with carcinoma penis followed by phimosis (25.5%), balanoposthitis (21.6%), and HIV (1.9%). A history of circumcision was present in only one patient, and it was performed just after birth.
The most common presenting symptoms were pain followed by discharge from the lesion and urinary symptoms. About 30% of patients had an ECOG (Eastern Cooperative Oncology Group) performance status score of 2 or more at the time of presentation. Glans penis (70.6%) was the most involved site followed by the shaft of the penis (29.4%). In 65.7% of cases, the primary lesion presented as an ulcero-proliferative growth, while the rest presented either as an ulcer or a lump on the penis. On examination, inguinal lymph node involvement and scrotal involvement were observed in 71.6% and 7.8% of patients, respectively.

5. Histopathologic Profile

Baseline tumor characteristics including TNM staging and histopathologic findings have been summarized in Table 2. The most common T stage at presentation was T3 in 36.2% of patients. Pathologic involvement of lymph nodes at diagnosis was present in 42.1% of patients. Distant metastases at diagnosis were observed only in 3.8%. A majority (44.1%) had localized disease (stage I & II), while advanced or locally advanced disease was observed in 43.1%. Complete staging status was not available in 12.8% of cases. Status on lymphovascular invasion (LVI) and perineural invasion (PNI) were available only in about 40% of cases. The most common histology was moderately differentiated squamous cell carcinoma in 60.8% of cases. Rare histology (adenocarcinoma, basaloid, sarcomatoid) was observed in only 2.9% of patients.

6. Impact of Education, Rural Household, and Distance from Treatment Centre

Most of the patients (58.8%, n = 62) belonged to rural households and about half of the patients (50.9%, n = 52) had to travel ≥100 km for accessing cancer care. The patient had low education attainment with less than one-third (31.3%) having schooling at more than primary school, while 46.9% had received no formal education at all. Among patients with node-positive disease (n = 43), 29 (67.4%) patients attended primary school or had no formal education, and 30 (69.7%) patients belonged to rural areas. Similarly, among patients with stage III or IV disease (n = 44), 30 (68.1%) patients attended primary school or had no formal education, and 32 (72.7%) patients belonged to rural areas. Differences in baseline characteristics based on education, rural household, and distance from the treatment centre have been elaborated in Table 3.
There was no significant difference in age, presence of risk factors (smoking, phimosis), ECOG PS, and duration of symptoms preceding diagnosis of carcinoma penis. Patients belonging to the rural household, residing >100 km away from the treatment centre, and those with lower educational attainment were more likely to have adverse tumor characteristics viz. higher T stage, node positivity, advanced stage at diagnosis, and presence of distance metastasis. However, the difference did not reach significance except for the T stage (based on distance from the treatment centre) and stage at the time of diagnosis (based on education).

7. Management

About 44% of patients had received some form of treatment before presentation to our centre. Details of previous treatment and relapse status at presentation to our institute are summarized in Supplementary Table S1. Of these patients, all patients except one (who received palliative chemotherapy) underwent initial surgical management. Partial penectomy was performed in two third of patients (66.6%) while the remaining underwent either circumcision (21.8%) or total penectomy (4.4%). Inguinal lymph node dissection (ILND) was performed in 8.8% and adjuvant radiotherapy was administered in 4.4% of patients, respectively. None of the patients received adjuvant chemotherapy. Post initial management 17.8% had a local relapse, 22.2% of patients had relapsed at distant (+/−local) sites, while 57.7% had no relapse.
The initial management of patients at our centre is summarized in Supplementary Table S2. The majority (76.8%) of patients underwent initial surgery, of which concomitant ILND was performed in 51.1% (n = 22) patients while the rest had only SLNB or ILND later. Curative intent brachytherapy with external beam radiation therapy (EBRT) was delivered in 3.6% (n = 2). Among patients undergoing surgery, 88.4% had organ preservation surgery (partial penectomy) and only 11.6% of patients underwent total penectomy. Patients belonging to rural areas (66.6%), residing farther from the specialized centre (66.6%), and low education level (83.3%) were more likely to undergo total penectomy. Palliative chemotherapy or radiotherapy was started in 17.8% of patients and one patient (1.8%) was advised best supportive care (BSC).
Overall chemotherapy was administered in 24 patients in adjuvant (n = 6) or palliative settings (n = 18). Six patients were started on adjuvant chemotherapy either TIP (paclitaxel, ifosfamide, and cisplatin) or TP (paclitaxel and carboplatin). Palliative chemotherapy consisted of either TP/TIP in 66.6% (n = 12) patients, methotrexate with/without TKI (Tyrosine kinase inhibitors) in 22.2% (n = 4), or TKI alone in 11.1% (n = 2). Gefitinib or erlotinib was used in 11.1% (n = 2) of patients with poor performance status. The objective response rate (ORR) to palliative systemic therapy was 50%. Responses were observed in three out of four patients on TKI. Radiotherapy was administered in 39 patients including six patients receiving definitive radiotherapy, adjuvant in 19 patients, and 14 in a palliative setting.

8. Survival

Of 80 patients treated with curative intent, 40 patients had relapsed at the last follow-up. Median relapse-free survival (RFS) was 57.6 months (15.8 months not reached [NR]) (Figure 1). On univariate (Table 4) analysis poor performance status, low serum albumin, higher t-stage, nodal involvement, and advanced stage were significant predictors for relapse. Education status, rural versus urban dwelling, and distance from the hospital were not predictive of relapse. However, on multivariate analysis, stage at presentation (hazard ratio [HR] 1.75; 95% confidence interval [CI] 1.07 to 2.85; p value 0.02) remained statistically significant predictors for relapse.
At the last follow-up, 43 patients out of a total of 102 had died. Median overall survival (OS) was 83.9 months (32.5 months to NR) (Figure 1). On univariate analysis poor performance status, low serum albumin, presence of PNI, higher T stage, nodal involvement, metastatic disease, and advanced stage were significant predictors for death. Education status, rural versus urban dwelling, and distance from the hospital were not predictive. However, on multivariate analysis, nodal involvement (HR 3.58; 95% CI 1.52 to 8.41; p value 0.003), and metastatic disease (HR 3.55; 95% CI 1.02 to 12.34; p value 0.045) remained statistically significant predictors. Median survival for stage I and stage II were not reached, while for stage III and stage IV were 39.2 months (13.8 months not reached) and 11.2 months (3.2 months not reached), respectively.
There was no impact of distance, education, or rural/urban dwelling on RFS and OS in carcinoma penis patients. Univariate and multivariate analysis (Table 4) suggest that none of these factors predicted RFS and OS.

9. Discussion

Penile cancer poses a considerable social and economic burden in developing nations [28]. In this study, health records of 102 patients with carcinoma penis treated at a tertiary care centre in India were analyzed to determine the clinical profile, treatment patterns, outcomes, and predictors.
The median age in our study was 55 years which is similar to that reported in other studies from India [29,30]. Penile carcinoma has a median age of around 60 years in Western countries and a decade younger in developing nations [31,32,33]. Smoking (27.5%), phimosis (25.5%), balanoposthitis (21.6%), and HIV (1.9%) were commonly observed risk factors in this study. Poor hygiene, genital warts, infections, phimosis, HIV, HPV, and smoking are known risk factors, while circumcision at birth is protective. In our series, only one patient had a prior history of circumcision at birth [9,10].
Carcinoma penis most commonly presents as a painless lump or ulcer, however more than half of patients in the current study presented with painful ulcer-proliferative growth [5]. Discharge and dysuria were also complained of by one-third of patients. Similarly, clinically inguinal lymphadenopathy (70%) and scrotal involvement (8%) were observed in a high proportion of patients than reported in the literature [7]. Patients had higher T stage (only 25% ≤ T2) and N stage (N+ in 42.1%) as reported from various developing nations [33,34]. Overall, 43.1% of patients had either stage III or IV at presentation. This may be due to more advanced diseases at presentation due to delays in healthcare access.
Well or moderately differentiated carcinoma was observed in about 90% of patients, while poorly differentiated and rare histology was reported in <10%. This is similarly reported in other studies [29,30]. LVI or PNI was reported in only 40% of patients and was not available for the rest.
About 80% of patients were treated with curative intent with initial surgery. Patients with localized disease underwent penectomy with/without inguinal lymph node dissection. However, most patients treated at non-specialized centres did not undergo the required inguinal lymph node staging or organ preservation approaches due to a lack of facilities [35,36]. A study by the United States (US) National Cancer Database reported that only 27.2% of patients with carcinoma penis underwent inguinal lymphadenectomy. Further, the procedure was associated with increased OS. Most patients treated at our centre had lymph node staging in form of SLNB or ILND.
Palliative therapy was initiated in about 20% of patients with the majority receiving platinum-based therapy [31]. Patients with poor PS were started on TKIs with or without methotrexate. Although the numbers are small, good responses (three out of four) were observed with TKI-based therapy in a palliative setting. Other EGFR inhibitors have also shown some promise but these are all in retrospective series [37,38].
Median OS for stage I and stage II were not reached, while for stage III and stage IV it was 39.2 months and 11.2 months, respectively. Advanced stage, higher T stage, nodal involvement, metastatic disease, poor ECOG PS at diagnosis, low serum albumin, and presence of PNI, were significant predictors for death. However, the stage was not a significant predictor for OS on multivariate analysis and only nodal involvement, and metastatic disease retained significance. Various predictive factors for OS have been identified but nodal involvement is the most consistent [38,39,40,41,42,43,44].
Most of the patients belonged to rural areas, had some or no formal education, and resided far from the tertiary centre. Due to this access to appropriate healthcare may be challenging and most patients have locally advanced disease when they are diagnosed [33,34]. Rural habitation and low education were associated with higher T stage, higher N stage as well as Stage III/IV. Similarly, patients belonging to rural areas and with lower educational attainment had higher chances of undergoing suboptimal initial surgery or radical penectomy. However, there was no impact of these factors on RFS or OS in this study. Studies have identified rural habitation as a predictor of higher stage and poor outcomes [45,46]. Similarly, lower education is also associated with delayed diagnosis, higher disease stage, inferior outcomes, and a higher likelihood of radical penectomy [44,45,46,47].
In a single registry-based study from an urban population in India, the impact of education, religion, marital status, and age was evaluated in patients diagnosed with carcinoma cervix and carcinoma penis. Illiterate patients had double the incidence of carcinoma penis as compared to literate patients [48].
This study highlights the impact of education and rural dwelling on the clinical presentation, treatment pattern, and outcomes in carcinoma penis. There is a scarcity of published literature in this area and thus our results advocate the need to raise awareness about carcinoma penis in rural areas. However, the study has inherent biases associated with the small single-centre retrospective studies. Due to the absence of data on household income, occupation, and other determinants, we were unable to assess the impact of all socioeconomic factors on the outcomes.

10. Conclusions

Carcinoma penis is diagnosed a decade earlier in India and patients have more advanced disease at presentation. This may be attributable to low education status and rural habitation. Nodal involvement and the presence of metastatic disease at diagnosis are independent predictors of overall survival.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/curroncol30050345/s1, Table S1: Summary of management of patients treated from other centre; Table S2: Summary of initial management of patients with carcinoma penis.

Author Contributions

Conception and design: V.G. and A.B. Collection and assembly of data: V.G. and A.B. Data analysis and interpretation: V.G. and A.B. Manuscript writing: V.G., M.R., K.P.H., R.K.S., A.S., S.K. and A.B. Accountable for all aspects of the work: V.G., M.R., K.P.H., R.K.S., A.S., S.K. and A.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Prior approval taken from the Institute’s Ethics Committee for Post Graduate Research (IEC-1062/03.10.2020), All India Institute of Medical Science (AIIMS), New Delhi.

Informed Consent Statement

As this is a retrospective study, individual consent was not required by the Institute’s Ethics Committee.

Data Availability Statement

The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021, 71, 7–33. [Google Scholar] [CrossRef]
  2. Barnholtz-Sloan, J.S.; Maldonado, J.L.; Pow-sang, J.; Guiliano, A.R. Incidence trends in primary malignant penile cancer. Urol. Oncol. Semin. Orig. Investig. 2007, 25, 361–367. [Google Scholar] [CrossRef]
  3. Misra, S.; Chaturvedi, A.; Misra, N.C. Penile carcinoma: A challenge for the developing World. Lancet Oncol. 2004, 5, 240–247. [Google Scholar] [CrossRef]
  4. Mathur, P.; Sathishkumar, K.; Chaturvedi, M.; Das, P.; Sudarshan, K.L.; Santhappan, S.; Nallasamy, V.; John, A.; Narasimhan, S.; Roselind, F.S.; et al. Cancer Statistics, 2020: Report from National Cancer Registry Programme, India. JCO Glob. Oncol. 2020, 6, 1063–1075. [Google Scholar] [CrossRef]
  5. Ritchie, A.W.S.; Foster, P.W.; Fowler, S. BAUS Section of Oncology. Penile cancer in the UK: Clinical presentation and outcome in 1998/99. BJU Int. 2004, 94, 1248–1252. [Google Scholar] [CrossRef]
  6. Hernandez, B.Y.; Barnholtz-Sloan, J.; German, R.R.; Giuliano, A.; Goodman, M.T.; King, J.B.; Negoita, S.; Villalon-Gomez, J.M. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998–2003. Cancer 2008, 113 (Suppl. 10), 2883–2891. [Google Scholar] [CrossRef] [PubMed]
  7. Heyns, C.F.; Mendoza-Valdés, A.; Pompeo, A.C.L. Diagnosis and staging of penile cancer. Urology 2010, 76 (Suppl. 1), S15–S23. [Google Scholar] [CrossRef] [PubMed]
  8. Sanchez, D.F.; Soares, F.; Alvarado-Cabrero, I.; Cañete, S.; Fernández-Nestosa, M.J.; Rodríguez, I.M.; Barreto, J.; Cubilla, A.L. Pathological factors, behavior, and histological prognostic risk groups in subtypes of penile squamous cell carcinomas (SCC). Semin. Diagn. Pathol. 2015, 32, 222–231. [Google Scholar] [CrossRef]
  9. Dillner, J.; von Krogh, G.; Horenblas, S.; Meijer, C.J. Etiology of squamous cell carcinoma of the penis. Scand. J. Urol. Nephrol. Suppl. 2000, 205, 189–193. [Google Scholar] [CrossRef] [PubMed]
  10. Daling, J.R.; Madeleine, M.M.; Johnson, L.G.; Schwartz, S.M.; Shera, K.A.; Wurscher, M.A.; Carter, J.J.; Porter, P.L.; Galloway, D.A.; McDougall, J.K.; et al. Penile cancer: Importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int. J. Cancer 2005, 116, 606–616. [Google Scholar] [CrossRef]
  11. Miralles-Guri, C.; Bruni, L.; Cubilla, A.L.; Castellsagué, X.; Bosch, F.X.; de Sanjosé, S. Human papillomavirus prevalence and type distribution in penile carcinoma. J. Clin. Pathol. 2009, 62, 870–878. [Google Scholar] [CrossRef]
  12. Mortensen, G.L.; Jakobsen, J.K. Patient perspectives on quality of life after penile cancer. Dan. Med. J. 2013, 60, A4655. [Google Scholar]
  13. Bezerra, A.L.; Lopes, A.; Santiago, G.H.; Ribeiro, K.C.; Latorre, M.R.; Villa, L.L. Human papillomavirus as a prognostic factor in carcinoma of the penis: Analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer 2001, 91, 2315–2321. [Google Scholar] [CrossRef] [PubMed]
  14. Velazquez, E.F.; Ayala, G.; Liu, H.; Chaux, A.; Zanotti, M.; Torres, J.; Cho, S.I.; Barreto, J.E.; Soares, F.; Cubilla, A.L. Histologic grade and perineural invasion are more important than tumor thickness as predictor of nodal metastasis in penile squamous cell carcinoma invading 5 to 10 mm. Am. J. Surg. Pathol. 2008, 32, 974–979. [Google Scholar] [CrossRef]
  15. Pandey, D.; Mahajan, V.; Kannan, R.R. Prognostic factors in node-positive carcinoma of the penis. J. Surg. Oncol. 2006, 93, 133–138. [Google Scholar] [CrossRef]
  16. Escande, A.; Haie-Meder, C.; Mazeron, R.; Maroun, P.; Cavalcanti, A.; de Crevoisier, R.; Schernberg, A.; Marsolat, F.; Blanchard, P.; Martinetti, F.; et al. Brachytherapy for Conservative Treatment of Invasive Penile Carcinoma: Prognostic Factors and Long-Term Analysis of Outcome. Int. J. Radiat. Oncol. Biol. Phys. 2017, 99, 563–570. [Google Scholar] [CrossRef] [PubMed]
  17. Djordjevic, M.L.; Palminteri, E.; Martins, F. Male genital reconstruction for the penile cancer survivor. Curr. Opin. Urol. 2014, 24, 427–433. [Google Scholar] [CrossRef] [PubMed]
  18. Pizzocaro, G.; Algaba, F.; Horenblas, S.; Solsona, E.; Tana, S.; Van Der Poel, H.; Watkin, N.A. EAU penile cancer guidelines 2009. Eur. Urol. 2010, 57, 1002–1012. [Google Scholar] [CrossRef]
  19. Van Poppel, H.; Watkin, N.A.; Osanto, S.; Moonen, L.; Horwich, A.; Kataja, V. Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013, 24, vi115–vi124. [Google Scholar] [CrossRef]
  20. Nicholson, S.; Hall, E.; Harland, S.J.; Chester, J.D.; Pickering, L.; Barber, J.; Elliott, T.; Thomson, A.; Burnett, S.; Cruickshank, C.; et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br. J. Cancer 2013, 109, 2554–2559. [Google Scholar] [CrossRef] [PubMed]
  21. Pagliaro, L.C.; Williams, D.L.; Daliani, D.; Williams, M.B.; Osai, W.; Kincaid, M.; Wen, S.; Thall, P.F.; Pettaway, C.A. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010, 28, 3851–3857. [Google Scholar] [CrossRef]
  22. Djajadiningrat, R.S.; Bergman, A.M.; van Werkhoven, E.; Vegt, E.; Horenblas, S. Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer. Clin. Genitourin. Cancer 2015, 13, 44–49. [Google Scholar] [CrossRef] [PubMed]
  23. Sharma, P.; Djajadiningrat, R.; Zargar-Shoshtari, K.; Catanzaro, M.; Zhu, Y.; Nicolai, N.; Horenblas, S.; Spiess, P.E. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. Urol. Oncol. 2015, 33, 496.e17–496.e23. [Google Scholar] [CrossRef] [PubMed]
  24. Theodore, C.; Skoneczna, I.; Bodrogi, I.; Leahy, M.; Kerst, J.M.; Collette, L.; Ven, K.; Marréaud, S.; Oliver, R.D.T. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2008, 19, 1304–1307. [Google Scholar] [CrossRef]
  25. Di Lorenzo, G.; Buonerba, C.; Federico, P.; Perdonà, S.; Aieta, M.; Rescigno, P.; D’Aniello, C.; Puglia, L.; Petremolo, A.; Ferro, M.; et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int. 2012, 110, E661–E666. [Google Scholar] [CrossRef] [PubMed]
  26. Edge, S.B.; Compton, C.C. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 2010, 17, 1471–1474. [Google Scholar] [CrossRef] [PubMed]
  27. Data Catalog. Available online: https://censusindia.gov.in/nada/index.php/catalog/?page=1&sort_by=popularity&sort_order=desc&ps=15 (accessed on 4 December 2022).
  28. Korkes, F.; Neves-Neto, O.C.; Wroclawski, M.L.; Tobias-Machado, M.; Pompeo, A.C.L.; Wroclawski, E.R. Parachute technique for partial penectomy. Int. Braz. J. Urol. 2010, 36, 198–201. [Google Scholar] [CrossRef]
  29. Mailankody, S.; Radhakrishnan, V.; Raja, A.; Ganesan, T.S.; Ganesan, P.; Dhanushkodi, M.; Joshua, T.; Sagar, T.G. Chemotherapy in carcinoma penis: Experience from a tertiary cancer centre in India. Ann. Oncol. 2017, 28, x83. [Google Scholar] [CrossRef]
  30. Shah, A.A.; Shah, H.A.; Panjwani, G.N.; Pandey, B.B.; Shah, N. Prognostic factors and 5-year survival of patients with carcinoma penis: Tertiary health center study. Indian J. Cancer 2016, 53, 309–312. [Google Scholar] [CrossRef]
  31. Patil, V.M.; Noronha, V.; Joshi, A.; Muddu, V.; Bhosale, B.; Bakshi, G.; Prabhash, K. Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise? Urol. Ann. 2014, 6, 18–22. [Google Scholar]
  32. Hegarty, P.K.; Kayes, O.; Freeman, A.; Christopher, N.; Ralph, D.J.; Minhas, S. A prospective study of 100 cases of penile cancer managed according to European Association of Urology guidelines. BJU Int. 2006, 98, 526–531. [Google Scholar] [CrossRef] [PubMed]
  33. Vieira, C.B.; Feitoza, L.; Pinho, J.; Teixeira-Júnior, A.; Lages, J.; Calixto, J.; Coelho, R.; Nogueira, L.; Cunha, I.; Soares, F.; et al. Profile of patients with penile cancer in the region with the highest worldwide incidence. Sci. Rep. 2020, 10, 2965. [Google Scholar] [CrossRef] [PubMed]
  34. Chalya, P.L.; Rambau, P.F.; Masalu, N.; Simbila, S. Ten-year surgical experiences with penile cancer at a tertiary care hospital in northwestern Tanzania: A retrospective study of 236 patients. World J. Surg. Oncol. 2015, 13, 71. [Google Scholar] [CrossRef]
  35. Correa, A.F.; Handorf, E.; Joshi, S.S.; Geynisman, D.M.; Kutikov, A.; Chen, D.Y.; Uzzo, R.G.; Viterbo, R.; Greenberg, R.E.; Smaldone, M.C. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J. Urol. 2018, 199, 1238–1244. [Google Scholar] [CrossRef] [PubMed]
  36. Hegarty, P.K.; Shabbir, M.; Hughes, B.; Minhas, S.; Perry, M.; Watkin, N.; Ralph, D.J. Penile preserving surgery and surgical strategies to maximize penile form and function in penile cancer: Recommendations from the United Kingdom experience. World J. Urol. 2009, 27, 179–187. [Google Scholar] [CrossRef]
  37. Carthon, B.C.; Ng, C.S.; Pettaway, C.A.; Pagliaro, L.C. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int. 2014, 113, 871–877. [Google Scholar] [CrossRef] [PubMed]
  38. Buonerba, C.; Di Lorenzo, G.; Pond, G.; Cartenì, G.; Scagliarini, S.; Rozzi, A.; Quevedo, F.J.; Dorff, T.; Nappi, L.; Lanzetta, G.; et al. Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. Front. Pharmacol. 2016, 7, 487. [Google Scholar] [CrossRef]
  39. Ornellas, A.A.; Kinchin, E.W.; Nóbrega, B.L.B.; Wisnescky, A.; Koifman, N.; Quirino, R. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J. Surg. Oncol. 2008, 97, 487–495. [Google Scholar] [CrossRef]
  40. Li, K.; Sun, J.; Wei, X.; Wu, G.; Wang, F.; Fan, C.; Yuan, H. Prognostic value of lymphovascular invasion in patients with squamous cell carcinoma of the penis following surgery. BMC Cancer 2019, 19, 476. [Google Scholar] [CrossRef]
  41. Kawase, M.; Takagi, K.; Kawada, K.; Ishida, T.; Tomioka, M.; Enomoto, T.; Fujimoto, S.; Taniguchi, T.; Ito, H.; Kameyama, K.; et al. Clinical Lymph Node Involvement as a Predictor for Cancer-Specific Survival in Patients with Penile Squamous Cell Cancer. Curr. Oncol. Tor. Ont. 2022, 29, 5466–5474. [Google Scholar] [CrossRef]
  42. Ficarra, V.; Akduman, B.; Bouchot, O.; Palou, J.; Tobias-Machado, M. Prognostic factors in penile cancer. Urology 2010, 76 (Suppl. 1), S66–S73. [Google Scholar] [CrossRef] [PubMed]
  43. Chung, E.; Yang, S.; White, L.; Wood, S.; Nicol, D. Lessons learnt in the management of primary invasive penile cancer in an Australian tertiary referral centre: Clinical outcomes with a minimum 48 months follow-up study. Korean J. Urol. 2015, 56, 125–130. [Google Scholar] [CrossRef] [PubMed]
  44. Huang, K.B.; Liu, R.Y.; Peng, Q.H.; Li, Z.S.; Jiang, L.J.; Guo, S.J.; Zhou, Q.H.; Liu, T.Y.; Deng, C.Z.; Yao, K.; et al. EGFR mono-antibody salvage therapy for locally advanced and distant metastatic penile cancer: Clinical outcomes and genetic analysis. Urol. Oncol. Semin. Orig. Investig. 2019, 37, 71–77. Available online: https://www.sciencedirect.com/science/article/pii/S1078143918304009 (accessed on 7 December 2022). [CrossRef] [PubMed]
  45. Attalla, K.; Paulucci, D.J.; Blum, K.; Anastos, H.; Moses, K.A.; Badani, K.K.; Spiess, P.E.; Sfakianos, J.P. Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database. Urol. Oncol. 2018, 36, 14.e17–14.e24. [Google Scholar] [CrossRef] [PubMed]
  46. Garcia, L.; Reis, L.O.; García-Perdomo, H.A. Living in a rural area as a risk factor for worst outcomes in penile cancer. Int. Braz. J. Urol 2021, 47, 1259–1263. Available online: http://www.scielo.br/j/ibju/a/TSSyg64w8wVWk9XyGYZLY5t/?lang=en (accessed on 27 October 2022). [CrossRef]
  47. Angulo-Lozano, J.C.; Musi, L.F.S.; Garcia, J.G. Disparities in Healthcare Access, Education, and Geographical Factors That Affect Surgical Outcomes in Penile Cancer. Cureus 2022, 14, 30068. Available online: https://www.cureus.com/articles/117614-disparities-in-healthcare-access-education-and-geographical-factors-that-affect-surgical-outcomes-in-penile-cancer (accessed on 27 October 2022). [CrossRef]
  48. Gajalakshmi, C.K.; Shanta, V. Association between cervical and penile cancers in Madras, India. Acta Oncol. 1993, 32, 617–620. [Google Scholar] [CrossRef]
Curroncol 30 00345 g001 550
Figure 1. Kaplan–Meir estimates of (a). Relapse-free survival (RFS) in total population (b). Relapse-free survival (RFS) is according to stage (c). Overall survival (OS) in total population (d). Overall survival (OS) according to the stage.
Figure 1. Kaplan–Meir estimates of (a). Relapse-free survival (RFS) in total population (b). Relapse-free survival (RFS) is according to stage (c). Overall survival (OS) in total population (d). Overall survival (OS) according to the stage.
Curroncol 30 00345 g001
Table
Table 1. Baseline clinical characteristics of patients with carcinoma penis.
Table 1. Baseline clinical characteristics of patients with carcinoma penis.
Characteristicsn = 102 (%)
Median age (IQR) in years55.5 (42–65)
Median symptom duration (IQR) months6.0 (4–12)
Risk factors
  Smoking28 (27.5)
  Phimosis26 (25.5)
  Balanoposthitis22 (21.6)
  HIV2 (1.9)
  Circumcision1 (0.9)
Symptoms
  Pain58 (56.8)
  Discharge34 (33.3)
  Urinary symptoms37 (36.3)
ECOG PS
  04 (3.9)
  167 (65.6)
  226 (25.5)
  32 (1.9)
  43 (2.9)
Tumor Characteristics
  Ulcero-proliferative growth67 (65.7)
  Lump20 (19.6)
  Ulcer15 (14.7)
Part of penis involved
  Glans72 (70.6)
  Shaft30 (29.4)
Inguinal lymph node (clinical)73 (71.6)
Scrotal involvement8 (7.8)
ECOG PS: Eastern Cooperative Oncology Group Performance Status, IQR interquartile range. Data summarized in frequency (percentage) except age and duration of symptoms which are mentioned in the median (IQR).
Table
Table 2. Baseline tumor characteristics of patients with carcinoma penis.
Table 2. Baseline tumor characteristics of patients with carcinoma penis.
Tumor Characteristicsn = 102 (%)
T stage
  T125 (24.5)
  T225 (24.5)
  T337 (36.2)
  T47 (6.9)
  TX8 (7.8)
N stage
  N048 (47.1)
  N18 (7.8)
  N223 (22.5)
  N312 (11.8)
  NX11 (10.8)
M Stage
  M096 (94.1)
  M14 (3.8)
  Not available2 (1.9)
Stage
  I22 (21.6)
  II23 (22.5)
  III29 (28.4)
  IV15 (14.7)
  Not available13 (12.8)
Lymphovascular invasion12/41 (29.3)
Perineural invasion11/41 (26.8)
Histology
  Well differentiated SCC30 (29.4)
  Moderately differentiated SCC62 (60.8)
  Poorly differentiated SCC7 (6.8)
  Others (Adenocarcinoma, Basaloid, Sarcomatoid)3 (2.9)
Table
Table 3. Differences in baseline characteristics of patients with carcinoma penis.
Table 3. Differences in baseline characteristics of patients with carcinoma penis.
CharacteristicsDistanceRural/UrbanEducation
<100 km
n = 50 (%)		≥100 km
n = 52 (%)		Rural
n = 60 (%)		Urban
n = 42 (%)		≤Primary
n = 58 (%)		>Primary
n = 33 (%)
Median age (IQR) in years58 (42–65)54.5 (40.5–62)55 (40.5–63.5)56.5 (42–66)57 (45–65)46 (40–62)
Duration of symptoms >6 months18 (36.0)24 (46.1)26 (43.3)16 (38.0)24 (41.3)14 (42.4)
Risk factors
Smoking16 (33.0)12 (23.0)16 (26.6)12 (28.5)18 (31.0)9 (27.2)
Phimosis14 (28.0)12 (23.0)14 (23.3)12 (28.5)15 (25.8)8 (24.2)
ECOG PS
0–133 (66.0)37 (71.1)42 (70.0)28 (66.6)43 (74.1)20 (60.6)
2–417 (34.0)15 (28.8)18 (30.0)14 (33.3)15 (25.8)13 (39.3)
Inguinal lymph node (clinical)38 (76.0)35 (67.3)43 (72.1)30 (71.4)40 (68.9)26 (78.7)
T stage
  T19 (18.0)16 (30.7)15 (25.0)10 (23.8)19 (32.7)4 (12.1)
  T212 (24.0)13 (25.0)15 (25.0)10 (23.8)13 (22.4)9 (27.2)
  T321 (42.0)16 (30.7)21 (35.0)16 (38.0)17 (29.3)17 (51.5)
  T41 (2.0)6 (11.5)7 (10.1)06 (10.3)1 (1.7)
N stage
  N022 (44.0)26 (50.0)25 (41.6)23 (54.7)26 (44.8)17 (51.5)
  N+20 (40.0)23 (44.2)30 (50.0)13 (30.9)29 (50.0)11 (18.9)
M Stage
  M11 (2.0)3 (5.7)4 (6.6)03 (5.1)1 (1.7)
Stage
  I7 (14.0)15 (28.8)13 (21.6)9 (21.4)16 (27.5)4 (12.1)
  II14 (28.0)9 (17.3)10 (10.6)13 (30.9)8 (13.7)12 (36.3)
  III13 (26.0)16 (30.7)19 (31.6)10 (23.8)20 (34.4)8 (24.2)
  IV6 (12.0)9 (17.3)13 (21.6)2 (4.7)10 (17.2)4 (12.1)
Lymphovascular invasion8/18 (44.4)4/23 (16.6)6/25 (24.0)6/16 (37.5)5/20 (25.0)7/21 (33.3)
Perineural invasion6/18 (33.3)5/24 (20.8)6/26 (23.0)5/15 (33.3)4/18 (22.2)6/20 (30.0)
Histology
WDSCC15 (30.0)15 (28.8)16 (26.6)14 (33.3)17 (29.3)9 (27.2)
MDSCC29 (58.0)33 (63.4)39 (65.0)23 (54.7)35 (60.3)23 (69.6)
PDSCC5 (10.0)2 (3.8)3 (5.0)4 (9.5)4 (6.8)1 (1.7)
Other histology *1 (2.0)2 (3.8)2 (3.3)1 (2.3)2 (3.4)0
ECOG PS Eastern Cooperative Oncology Group Performance Status, IQR interquartile range, MDSCC Moderately differentiated squamous cell carcinoma, PDSCC Poorly differentiated squamous cell carcinoma, WDSCC Well-differentiated squamous cell carcinoma. * Others include Adenocarcinoma, Basaloid, and Sarcomatoid histology. Data is summarized in frequency (percentage) except age which is mentioned in the median (IQR).
Table
Table 4. Predictors of RFS and OS in carcinoma penis.
Table 4. Predictors of RFS and OS in carcinoma penis.
ParameterRelapse Free SurvivalOverall Survival
Hazard Ratio (CI)p ValueHazard Ratio (CI)p Value
Univariate analysis
T stageT23.7 (1.1–11.6)0.00122.4 (0.7–8.0)0.007
T35.5 (1.7–17.0)6.1 (2.0–18.3)
T442.3 (4.1–428.5)5.2 (1.2–21.3)
LN positive2.4 (1.2–5.0)0.013.3 (1.1–6.6)0.0003
StageII4.2 (1.1–15.3)0.00511.0 (1.3–28.0)0.0002
III6.4 (1.7–23.5)18.7 (1.9–38.9)
IV10.7 (1.8–72.5)25.4 (2.2–86.1)
ECOG PS > 12.9 (1.5–5.7)0.0022.1 (1.1–3.8)0.023
Albumin0.5 (0.3–0.9)0.040.5 (0.3–0.8)0.01
PNI1.1 (0.78–1.57)0.623.6 (1.2–10.7)0.022
LVI1.0 (0.76–1.5)0.662.9 (0.98–8.7)0.054
Metastatic diseaseNot applicable 3.2 (1.0–10.7)0.049
Distance0.65 (0.35–1.2)0.180.60 (0.333–1.1)0.10
Education0.97 (0.50–1.9)0.941.00 (0.53–1.8)0.98
Rural/urban1.18 (0.63–2.2)0.591.02 (0.55–1.87)0.94
Multivariate analysis
T stage1.33 (0.55–3.2)0.521.19 (0.61–2.3)0.60
LN positive1.13 (0.22–5.6)0.873.58 (1.52–8.41)0.003
Stage1.75 (1.07–2.85)0.021.82 (0.67–4.9)0.23
ECOG PS > 10.81 (0.26–2.55)0.751.06 (0.45–2.5)0.87
Albumin0.57 (0.28–1.17)0.100.51 (0.25–1.06)0.075
PNI0.86 (0.28–2.6)0.740.78 (0.21–2.8)0.70
LVI0.94 (0.29–3.0)0.421.26 (0.32–4.9)0.73
Metastatic diseaseNot applicable3.55 (1.02–12.34)0.045
Distance0.53 (0.12–2.2)0.400.34 (0.09–1.2)0.09
Education0.67 (0.24–1.8)0.441.7 (0.68–4.6)0.23
Rural/urban0.56 (0.11–2.7)0.470.50 (0.12–2.0)0.33
CI confidence interval, ECOG PS: Eastern Cooperative Oncology Group Performance Status, LVI lymphovascular invasion, OS overall survival, PNI perineural invasion, RFS relapse-free survival. Statistically significant values highlighted in bold.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Garg, V.; Ray, M.; Haresh, K.P.; Sahoo, R.K.; Sharma, A.; Kaushal, S.; Batra, A. Clinical Profile and Predictors of Survival in Carcinoma Penis Patients. Curr. Oncol. 2023, 30, 4563-4574. https://doi.org/10.3390/curroncol30050345

AMA Style

Garg V, Ray M, Haresh KP, Sahoo RK, Sharma A, Kaushal S, Batra A. Clinical Profile and Predictors of Survival in Carcinoma Penis Patients. Current Oncology. 2023; 30(5):4563-4574. https://doi.org/10.3390/curroncol30050345

Chicago/Turabian Style

Garg, Vikas, Mukurdipi Ray, K. P. Haresh, Ranjit Kumar Sahoo, Atul Sharma, Seema Kaushal, and Atul Batra. 2023. "Clinical Profile and Predictors of Survival in Carcinoma Penis Patients" Current Oncology 30, no. 5: 4563-4574. https://doi.org/10.3390/curroncol30050345

APA Style

Garg, V., Ray, M., Haresh, K. P., Sahoo, R. K., Sharma, A., Kaushal, S., & Batra, A. (2023). Clinical Profile and Predictors of Survival in Carcinoma Penis Patients. Current Oncology, 30(5), 4563-4574. https://doi.org/10.3390/curroncol30050345

Article Metrics

Back to TopTop